the two rulebooks: what a thai clinic may say to australian patients

I have looked for a guide that covers both sets of advertising rules governing a Thai clinic marketing to Australian patients, in one place, and I could not find one. Bangkok agencies know the Thai side. Australian marketers know the TGA. Nobody publishes the pair, so here it is. One note before we start: this is general information for marketing planning, not legal advice, and specific decisions belong with your Thai counsel and, where relevant, Australian advice.

Rulebook one: Thailand approves before you publish

The foundation is the Medical Facility Act B.E. 2541 (1998), as amended by Act No. 4, B.E. 2559. Under section 38, as analysed by the law firm Tilleke & Gibbins, medical facility advertisements "must obtain approval before their publication". The approver is the Department of Health Service Support (DoHSS), the requirement has been in effect since 31 January 2018, and the only carve-out is an advertisement carrying nothing beyond the facility's name and address.

The practical shape of that rule matters for campaign planning:

• Approval takes 10 to 30 working days, with fees charged per page for print and per second for video. Every creative you want to run is a submission, a fee and a wait.
• Running an unapproved advertisement carries a fine of up to THB 20,000. Misleading content carries up to one year's imprisonment and/or THB 20,000.
• Ignoring an order to take an advertisement down costs THB 10,000 per day, every day, until you comply.

Enforcement is not theoretical, and it does not stop at the clinic's door. In a case over a misleading stem-cell campaign, reported criminal fraud convictions reached the doctor, the clinic owner and the advertising agency that made the material. As the person who would be your agency, I read that case with particular attention. It is a large part of why MediSiam's workflow is built around pre-approval rather than around asking forgiveness.

There is a second Thai layer, current to last month. The Medical Council's Notification No. 39/2567, as amended by No. 17/2569 and effective 3 July 2026, governs cosmetic-enhancement advertising by practitioners. As summarised by Mahanakorn Partners, such advertising must display the practitioner's "real first name, surname and medical license number". A nickname may appear only alongside the real name in identical "color, style and size". The scope explicitly includes social media, and sanctions run to suspension or revocation of the practitioner's licence. If your Instagram introduces your surgeon as "Dr Beam" with no licence number, that post is now a compliance problem.

Rulebook two: Australia limits what reaches its consumers

The Australian side is less about process and more about content, and it is stricter than most Thai marketers expect. The Therapeutic Goods Administration (TGA) administers the Therapeutic Goods Act 1989, and its current guidance states plainly: "Advertising prescription medicines or substances is prohibited under subsections 42DL(10) and 42DLB(7) of the Act, apart from limited circumstances."

For a cosmetic clinic, that prohibition covers most injectables, because most contain Schedule 4 prescription-only substances. The TGA's health services guidance, updated 18 June 2026, instructs advertisers: "do not refer to prescription medicines or substances – even indirectly", listing brand names, acronyms or abbreviations, colloquial names or nicknames, and hashtags that a consumer would read as a reference to a prescription medicine.

The TGA's June 2026 guidance on prescription medicine advertising spells out what "indirectly" means with examples. Prohibited references include trade names such as "Botox" and "Ozempic", class references such as "Wrinkle reduction injections" and "Weight-loss injections", colloquial names such as "Tox, Haytox", and, in the implied-references category, "Graphics of syringes, applicator pens, vials, capsules or pills associated with prescription medicines", including in logos. A syringe icon in your clinic's branding can itself be the breach. Consultation framing is not a loophole either: advertising consultations where the material implies a prescription could or will result is, on the TGA's guidance, likely unlawful.

Beneath the prescription-medicine rules sits a general standard that applies to therapeutic goods advertising broadly. Under section 8(1) of the Therapeutic Goods Advertising Code, an advertisement must "be accurate, balanced and not misleading or likely to be misleading" and must "only contain information that is substantiated by the advertiser prior to publication or dissemination". Substantiated before publication, not after a complaint. The penalties give the regime teeth: at the current $364 penalty unit, civil maximums run to $1.82 million for an individual and $18.2 million for a body corporate.

Does Australian law actually reach a clinic in Bangkok?

Here is where I will be more honest than a sales page usually is. The prohibition attaches to advertising directed at Australian consumers, and how far Australian law reaches an advertiser with no Australian presence is a live legal question. I am not going to pretend the boundary is settled, because it is not, and anyone who tells you a Thai clinic is definitely caught, or definitely safe, is selling certainty that does not exist.

But look at what each answer implies. If Australian law reaches you, conservative creative was mandatory. If it does not, conservative creative still costs you almost nothing, because the TGA's own guidance points to the compliant path: promote the consultation and the condition, the practitioner and the facility, the journey and the standards, not the prescription-only product. That framing is also simply better marketing to Australians, who have spent years seeing their own clinics advertise this way and who read product-pushing copy from overseas as a warning sign. Building to the stricter standard is the only strategy that wins under every version of the legal answer.

Creative that survives both rulebooks

Put the two rulebooks together and the shape of compliant work becomes clear. Every creative must be written to pass DoHSS pre-approval in Bangkok the first time, because each revision cycle costs weeks and fees. The same creative must avoid Australian prohibited territory, because it is aimed at Australian consumers. And everything must clear the accuracy and substantiation bar, which rules out the inflated claims that still litter this market.

That is why "built for pre-approval the first time" is MediSiam's workflow, not a slogan. We draft against both rulebooks before anything is submitted or published, and the deliverable is creative that survives both: material your Thai lawyer can submit without wincing and an Australian regulator can read without interest. In this market, boring paperwork is a competitive weapon. Clinics that treat compliance as an afterthought lose weeks per creative to resubmission, or run exposed on two fronts at once.

If you want to know what your current Australian-facing presence looks like, including where it sits against these rules, start with the free Australia Visibility Report. It shows what Australian patients actually find when they look for your clinic, with no access needed and no commitment. Request your visibility report.